Current stock page

Stock Analysis

Trevi Therapeutics, Inc. (TRVI) Stock Analysis

Trevi Therapeutics, Inc. (TRVI) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

TRVI Stock Analysis Summary

Trevi Therapeutics, Inc. (TRVI) currently has an AIQ Score of 63/100, indicating a neutral setup. Quality is the strongest factor at 82/100. Risk is the weakest current factor at 51/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

TRVI at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$13.65
AIQ Score63/100
Overall ViewNeutral
Technical Analysis ConsensusNeutral
Market Cap$2.18B
P/E Ratio (TTM)-35.2
Forward P/E—
EPS (Q3 FY2026)-$0.13
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta1.38
Volume1.1M
52-week range$9.82-$20.22
RSI 1448.45
50-Day SMA$14.03
200-Day SMA$14.52
Analyst Price Target—
Next Earnings—
As of Nov 13, 2026 · Market close

TRVITrevi Therapeutics, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Sector Leader

NeutralEdge 10/10
$13.65+$0.03 (+0.22%)

Latest quote

  • Momentum
    52
  • Value
    —
  • Quality
    82
  • Risk resilience
    51
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

TRVI Stock Analysis Summary

Trevi Therapeutics, Inc. (TRVI) currently has an AIQ Score of 63/100, indicating a neutral setup. Quality is the strongest factor at 82/100. Risk resilience is the weakest current factor at 51/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, TRVI has AIQ Score of 63/100 with Quality base of 82/100 and fading Risk resilience at 51/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Quality (82/100) leads while Risk resilience (51/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 0.22% stock move · TRVI classified in Biotechnology.

Current Evidence

NeutralTRVI is in a neutral AIQ regime; Quality is the strongest visible factor at 82/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is TRVI Bullish or Bearish Right Now?

TRVI currently has a neutral overall setup. Quality is the strongest factor at 82/100, while Risk Resilience is weakest at 51/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Quality is supportive at 82/100.
Bear Case
  • - Price is -6.00% below its 200-day SMA.

Current Consensus

TRVI's Technical Analysis Consensus is currently Neutral, with 19 buy, 8 neutral, and 19 sell votes. TRVI's 14-day RSI is 48.45, which places the stock in a neutral momentum range. TRVI's beta is 1.38, indicating greater market sensitivity than the broad market.

Signal Confidence
Moderate agreement

What Changed in TRVI?

The largest recent change in TRVI is Momentum moving up by 2.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.

AIQ Score
+0.0
Momentum
+2.0
Quality
-1.0
Risk
+0.0

What Would Change the TRVI Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

TRVI Decision Framework

Public evidence layers, setup checks, and risk context for Trevi Therapeutics, Inc..

Trevi Therapeutics, Inc. (TRVI) Stock Analysis

Trevi Therapeutics, Inc. has an AIQ Score of 63/100 in a Neutral regime. Quality is strongest at 82/100. Beta is 1.38, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextTRVI is in a Neutral AIQ regime with score 63/100.
Signal ConflictThe primary conflict is that quality leads at 82/100 while risk lags at 51/100.
Factor EvidenceMomentum 52/100 · Quality 82/100 · Risk 51/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Quality is the strongest factor at 82/100.

TimingWait

Momentum is 52/100 and RSI (14) is 48.5.

Regime fitWait

TRVI is in a Neutral regime at 63/100.

Risk controlWait

Risk factor is 51/100 with beta 1.38 and annual volatility 59.27%.

ConflictWait

Current conflict: quality leads at 82/100 while risk lags at 51/100.

AIQ Score
63/100
Price
$13.65
Beta
1.38
RSI (14)
48.5

TRVI Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

TRVI Fundamentals

TRVI valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$21.45M
Free cash flow
-$19.71M
View full TRVI fundamental analysis

TRVI Technical Analysis

TRVI technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Neutral
RSI 14
48.45
Price vs SMA-50
-2.72%
View full TRVI technical analysis

TRVI Stock Catalysts

Track TRVI earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
—
Analyst target
—
News items
3
View TRVI earnings and stock catalysts

TRVI Dividend Analysis

TRVI dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View TRVI dividend history and analysis

TRVI Financial Data

TRVI revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$0.13
Periods
8
View TRVI financials

TRVI Risk Analysis

TRVI volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.38
Risk score
51/100
1Y volatility
59.27%
View TRVI risk analysis

TRVI Stock News

TRVI stock news, market tone, recent headlines, and catalyst context.

News items
3
Updated
Nov 15, 2026
Sentiment
—
Read TRVI stock news

TRVI vs Biotechnology Peers

Current peer cohort: TRVI · TSHA · TVTX · TWST · TYRA. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
TRVI
Current stock
63/100—52/10051/1000.5259.27%Current
TSHA
Taysha Gene Therapies, Inc.
35/100—32/10037/1000.3270.69%TRVI vs TSHA
TVTX
Travere Therapeutics, Inc.
64/10069/10067/10055/1000.8762.28%TRVI vs TVTX
TWST
Twist Bioscience Corporation
64/10058/10084/10032/1001.9484.18%TRVI vs TWST
TYRA
Tyra Biosciences, Inc.
49/100—27/10045/1000.6567.91%TRVI vs TYRA
Pairwise Compare links: TSHA · TVTX · TWST · TYRATRVI vs TSHATRVI vs TVTXTRVI vs TWSTTRVI vs TYRACompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a TRVI stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for TRVI: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-35.2
As of Nov 13, 2026
Revenue growth
—
Gross margin
0.00%
Current debt / equity
0
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$21.45M
Quarter free cash flow
-$19.71M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Mixed
RSI 14
48.45
MACD
0.13

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
51/100
Beta
1.38
Annual volatility
59.27%
Max drawdown
-39.08%

TRVI Stock FAQ

What is TRVI stock price today?

Trevi Therapeutics, Inc.'s current stock price is $13.65. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is TRVI bullish or bearish right now?

TRVI's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is TRVI's market cap?

TRVI's market cap is $2.18B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is TRVI's current P/E ratio?

TRVI's current P/E ratio is -35.2 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is TRVI's RSI?

TRVI's 14-day RSI is 48.45 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is TRVI above its 50-day and 200-day moving averages?

TRVI is -2.72% from its 50-day SMA and -6.00% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is TRVI's next earnings date?

TRVI's next earnings date is a key event to check before making a decision. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does TRVI pay a dividend?

TRVI's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.